Good MorningEquity markets ended the week, month and year on a sour note falling more than 1.0% at the low of the day on Friday to cap off a year of selling in the stock market. The S&P 500 shed more than 25% at the depths of the correction and may reach those levels again in 2023. The risk for the market this year is not only a worsening outlook for corporate earnings but a growing possibility for a deep recession.
This week may be another week of listless trading but the action will heat up soon enough. The calendar Q4 2022 earnings reporting season begins with releases from JPMorgan and other major banks along with key reports from other sectors. As it is, the market is expecting to see S&P 500 earnings fall by roughly 3.0% on average which will be the first decline in earnings since the depths of the pandemic in Q3 of 2020. Featured: How to Collect Up To $5,917/mo From Trump’s Made In USA Boom (Ad) 
|
Markets | | |
At first glance, it might seem like Kintara Therapeutics Inc (Nasdaq: KTRA) would not be a good investment. After all, analysts gave the stock a HOLD rating after its Q3 earnings report in November. However, that rating alone is not enough to understand the full scope of possibility in its future,... Read the Full Story |
|
From Our Partners | | A Historic Gold Announcement Is About to Rock Wall Street?
For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains. | | Click here to get Garrett’s Top Four picks now. |
|
Markets | | |
2022 has been challenging for big tech. While the QQQ NASDAQ Index tracking stock (NYSE: QQQ) is down more than 33% from its post-pandemic peak names like Facebook (cough Meta Platforms (NASDAQ: META)), Amazon (NASDAQ: AMZN) and Salesforce.com (NYSE: CRM) are down more than 50%, and the figure may... Read the Full Story |
|
Stocks | | |
This article highlights three high-yield dividend stocks that investors will want to consider buying in 2023. Investors are expecting another volatile year. And owning dividend stocks is a time-honored way to stay invested during market volatility.
Because these companies pay shareholders ... Read the Full Story |
|
From Our Partners | | New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun.
Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation. | | See Altucher’s Trump crypto prediction here |
|
Tech | | | Wall Street capped a quiet day of trading with more losses Friday, as it closed the book on the worst year for the S&P 500 since 2008.
The benchmark index finished with a loss of 19.4% for 2022, or 18.1%, including dividends. It's just its third annual decline since the financial... Read the Full Story |
|
Tech | | | A relatively light day of trading on Wall Street ended Thursday with a broad rally for stocks as investors welcomed new jobless benefits data that shows the labor market remains strong.
The S&P 500 rose 1.7%, with roughly 95% of stocks within the benchmark index closing higher. Th... Read the Full Story |
|
From Our Partners | | Bitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity.
While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video. | | Watch the Bitcoin Skimming strategy here |
|
Stocks | | | Stocks rallied on Wall Street in afternoon trading Thursday as investors reviewed the latest government update showing that the labor market remains strong.
The S&P 500 rose 1.8% as of 1:46 p.m. Eastern. More than 95% of stocks within the benchmark index gained ground. It's the la... Read the Full Story |
|
Markets | | | Stocks fell in afternoon trading on Wall Street Friday as major indexes close out a dismal year with lingering concerns about stubbornly hot inflation and a potential recession.
The S&P 500 fell 0.8% as of 3:13 p.m. Eastern. The index, which is considered a benchmark for the broad... Read the Full Story |
|
Markets | | |
Power generation and energy storage systems maker Generac Holdings Inc. (NASDAQ: GNRC) stock has been a heartbreaker. Shares were trading at a high of $524.31 just over a year ago before shares fell to a new weekly lower low of $86.29 in late December, falling below its pre-pandemic levels.
With ... Read the Full Story |
|
Markets | | | Democrats in Congress released thousands of pages of former President Donald Trump's tax returns Friday, providing the most detailed picture to date of his finances over a six-year period, including his time in the White House, when he fought to keep the information private in a break with decades o... Read the Full Story |
|
Markets | | |
Microsoft Corporation (NASDAQ: MSFT) scooped up a 4% stake in the London Stock Exchange Group (LON: LSEG) this month. Investors might wonder what significance this will have for the company moving forward.
As part of the acquisition, the companies will work to create a "centralized, financia... Read the Full Story |
|
Monday's Early Bird Stock Of The Day Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California. | | View Today's Stock Pick |
|
